ASSEMBLY BIOSCIENCES, INC.
ASMB · XNASCIK 1426800fmd_09J0TWW295906J8H6R9X7TKD3HManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2007 to Sep 30, 2026, 69 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 9 | 15 | 16 | 79 | 6 | 0 | 7 | 29 | 72 |
| Realized investment gains (losses) | – | – | – | – | – | – | 0 | 0 | 0 | – |
| Research and development | 33 | 44 | 73 | 86 | 107 | 69 | 70 | 49 | 56 | 65 |
| Total operating expenses | – | 61 | 108 | 119 | 144 | 139 | 94 | 72 | 74 | 84 |
| Operating income | (45) | (52) | (93) | (103) | (65) | (133) | (94) | (65) | (45) | (12) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 0 | 0 | 3 | 4 | 3 | 0 | 1 | 3 | 6 | 6 |
| Income before taxes | (45) | (52) | (90) | (98) | (62) | (132) | (93) | (61) | (40) | (6) |
| Income tax expense | (1) | (9) | 1 | (1) | 0 | (3) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (44) | (43) | (91) | (98) | (62) | (130) | (93) | (61) | (40) | (6) |
| Net income | (44) | (43) | (91) | (98) | (62) | (130) | (93) | (61) | (40) | (6) |